Core Scientific, Inc. (Nasdaq: CORZW, CORZZ) Reports Q2 2026 Results

Key Points From the Quarterly Report Ended June 30, 2026

• Revenue Growth: Core Scientific reported revenues of \$279.4 million for the three months ended June 30, 2026, a significant increase compared to \$158.2 million in the same period last year and \$100.2 million for the prior quarter.
• Gross Profit: Gross profit for the quarter reached \$100.2 million, sharply higher than the \$13.2 million gross profit in Q2 2025.
• Net Loss: Despite revenue growth, the company reported a substantial net loss of (\$360.5 million) for the quarter, compared to a net loss of (\$73.3 million) in Q2 2025. The loss per share for the quarter was (\$3.32).
• Operating Loss: Operating loss for Q2 2026 was reported at (\$388.9 million), a significant increase from (\$73.3 million) in the same period last year.
• Fair Value Adjustment on Warrants and Contingent Value Rights: The company recorded a non-cash fair value adjustment of \$1.08 billion for the quarter, which heavily impacted the net loss.
• Balance Sheet Position: As of June 30, 2026, Core Scientific held \$1.77 million in cash and cash equivalents and \$49.7 million in digital assets. Total assets stood at \$2.35 billion. Stockholders’ deficit was (\$962.7 million), reflecting the company’s ongoing losses and adjustments.
• Weighted Average Shares Outstanding: For Q2 2026, the company had 325.3 million weighted-average shares outstanding.
• Warrants and Securities: The report lists two classes of warrants: one exercisable at \$6.81 per share (CORZW) and another at \$0.01 per share (CORZZ), both trading on The Nasdaq Global Select Market. There are 321,441,000 shares of common stock outstanding as of July 23, 2026.
• Compliance and Reporting: Core Scientific confirms that it has filed all required reports and is not a shell company. The company is still subject to bankruptcy reporting requirements, indicating recent emergence from bankruptcy proceedings.

Shareholder-Relevant and Potentially Price-Sensitive Information

• Significant Non-Cash Charges: The massive fair value adjustment on warrants and contingent value rights (\$1.08 billion) is a non-cash charge but has a dramatic effect on reported losses. This may prompt questions about the capital structure, potential dilution, and future financial strategy.
• Continuing Stockholders’ Deficit: The company continues to operate with a substantial stockholders’ deficit, which may limit its financial flexibility, impact creditworthiness, and raise concerns about future capital needs or dilution.
• Emergence from Bankruptcy: Core Scientific has recently exited bankruptcy. While it is in compliance with reporting, this history may influence investor sentiment, lending terms, and the company’s ability to raise new capital.
• Warrants Structure: The large number of outstanding warrants, especially those exercisable at a nominal price (\$0.01), could result in significant dilution for existing shareholders if exercised.
• Digital Asset Holdings: The company’s \$49.7 million in digital assets exposes it to cryptocurrency price volatility, which could materially impact future results.
• Forward-Looking Statements and Risks: The company highlights ongoing risks related to scaling operations, securing energy, and sourcing talent. It also notes that forward-looking statements may not materialize due to factors beyond management’s control.

Detailed Financial Overview

Additional Information

• Forward-Looking Statements: Core Scientific warns investors that its projections and estimates are forward-looking and subject to significant risks, including market volatility, operational challenges, and other uncertainties.
• Ongoing Risks: The company points to risks around electricity sourcing, supply chain, talent acquisition, and the broader cryptocurrency market.
• Regulatory Compliance: The company is current with all SEC filings and is not classified as a shell company or an emerging growth company.
• Share Structure: With over 321 million shares outstanding and a significant number of warrants, investors should monitor for potential dilution events.

Potential Share Price Movers

• Large Non-Cash Charges: The \$1.08 billion non-cash adjustment could be interpreted negatively by the market, even though it does not affect cash flow.
• Persistent Deficit and Recent Bankruptcy: The ongoing stockholders’ deficit and recent bankruptcy may weigh on investor confidence and could affect access to capital.
• Revenue Growth vs. Losses: While top-line growth is strong, the inability to translate that into profitability may be a concern for investors.
• Cryptocurrency Exposure: The company’s digital asset holdings are subject to market volatility, which could materially affect future reported results.
• Warrants Structure: The large volume of low-price warrants may create overhang and pressure on the share price if exercised.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information is based on the company’s unaudited quarterly filing and may be subject to change. Investors should consult the full SEC filings and their financial advisor before making any investment decisions. The author and publisher assume no liability for investment actions taken based on this article.

View Core Scientific, Inc./tx Historical chart here